Category Archives: Blog

INTERACT vs Pre-IND Meeting: Which FDA Meeting to Request

The first conversation a sponsor has with the FDA often sets the trajectory for everything that follows. INTERACT is more of a “blue-sky” meeting and typically takes place before a Pre-IND meeting. The two serve different purposes, so it is … Continue reading →

Posted in Blog | Comments Off on INTERACT vs Pre-IND Meeting: Which FDA Meeting to Request

Fast Track vs. Breakthrough Therapy Designation: Understanding the Key Differences

Sponsors developing therapies for serious conditions have four FDA expedited programs available to them. Two of those programs, Fast Track and Breakthrough Therapy, are development-stage designations that shape how a sponsor interacts with FDA long before an NDA or BLA … Continue reading →

Posted in Blog | Comments Off on Fast Track vs. Breakthrough Therapy Designation: Understanding the Key Differences

Understanding FDA Review Structure: Why Your Audience Matters in Regulatory Strategy

Sponsors often talk about “the FDA” as if it were a single decision-maker with one set of expectations. It is not. The U.S. Food and Drug Administration is composed of multiple centers, offices, and review divisions, each with its own … Continue reading →

Posted in Blog | Comments Off on Understanding FDA Review Structure: Why Your Audience Matters in Regulatory Strategy

Orphan Drug Designation by the European Medicines Agency (EMA ODD)

For biotech and pharmaceutical companies developing therapies for rare diseases, securing orphan drug designation in Europe is one of the most consequential regulatory milestones in a program’s lifecycle. It unlocks ten years of market exclusivity, fee reductions, protocol assistance, and … Continue reading →

Posted in Blog | Comments Off on Orphan Drug Designation by the European Medicines Agency (EMA ODD)

Expedited Programs Beyond Orphan Designation

When developing a drug for a rare disease, orphan drug designation is often the first regulatory milestone on the list. But it is not the only incentive the FDA has created to help promising therapies reach patients faster. For sponsors … Continue reading →

Posted in Blog | Comments Off on Expedited Programs Beyond Orphan Designation

A Win for Rare Pediatric Disease Drug Innovation: The RPDD & PRV Program Is Reauthorized Through 2029, and OOC Is Ready

February 3, 2026 was a significant day for the rare pediatric disease community. The Consolidated Appropriations Act of 2026 was signed into law, reauthorizing the Rare Pediatric Disease Designation Priority Review Voucher (RPDD PRV) program through September 30, 2029. After … Continue reading →

Posted in Blog | Comments Off on A Win for Rare Pediatric Disease Drug Innovation: The RPDD & PRV Program Is Reauthorized Through 2029, and OOC Is Ready

Tropical Disease Priority Review Vouchers (PRVs) – How They Work

The Tropical Disease Priority Review Voucher is one of FDA’s most valuable incentives for drug development. These vouchers have sold on the open market for approximately $160 million or more, creating a powerful financial incentive for sponsors developing treatments in … Continue reading →

Posted in Blog | Comments Off on Tropical Disease Priority Review Vouchers (PRVs) – How They Work

FDA Orphan Drug Designation for Rare Cancers: U.S. Eligibility Guide

Understanding FDA Incentives for Rare Conditions – Eligible Cancers For sponsors developing treatments for rare cancers, FDA’s Orphan Drug Designation (ODD) offers powerful incentives that can transform your development strategy. These benefits include tax credits, fee waivers, market exclusivity, and … Continue reading →

Posted in Blog | Comments Off on FDA Orphan Drug Designation for Rare Cancers: U.S. Eligibility Guide

Guide to IND-Enabling Studies: Prep for Clinical Trials

What Are IND Applications For? Before investigational drugs can be tested in humans, sponsors must obtain clearance from the U.S. Food and Drug Administration (FDA) through an Investigational New Drug (IND) application. This submission must include results from a series … Continue reading →

Posted in Blog | Comments Off on Guide to IND-Enabling Studies: Prep for Clinical Trials

Top Reasons FDA Issues Deficiency Letters for Orphan Drug Designation (ODD) Applications

The FDA is highly supportive of orphan drug development, but that doesn’t mean every Orphan Drug Designation (ODD) application gets approved on the first review cycle. Many sponsors still end up with deficiency letters—and they tend to focus on the … Continue reading →

Posted in Blog | Comments Off on Top Reasons FDA Issues Deficiency Letters for Orphan Drug Designation (ODD) Applications